Lisata Therapeutics Statistics
Share Statistics
Lisata Therapeutics has 8.62M
shares outstanding. The number of shares has increased by 3.76%
in one year.
| Shares Outstanding | 8.62M |
| Shares Change (YoY) | 3.76% |
| Shares Change (QoQ) | 2.68% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 540 |
| FTD / Avg. Volume | 4% |
Short Selling Information
The latest short interest is 28.54K, so 0.34% of the outstanding
shares have been sold short.
| Short Interest | 28.54K |
| Short % of Shares Out | 0.34% |
| Short % of Float | 0.42% |
| Short Ratio (days to cover) | 1.7 |
Valuation Ratios
The PE ratio is -1.24 and the forward
PE ratio is -2.4.
Lisata Therapeutics's PEG ratio is
0.18.
| PE Ratio | -1.24 |
| Forward PE | -2.4 |
| PS Ratio | 24.82 |
| Forward PS | 0.4 |
| PB Ratio | 0.84 |
| P/FCF Ratio | -1.28 |
| PEG Ratio | 0.18 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Lisata Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.16,
with a Debt / Equity ratio of 0.
| Current Ratio | 6.16 |
| Quick Ratio | 6.16 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $38,461.54 |
| Profits Per Employee | $-768,653.85 |
| Employee Count | 26 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -798K |
| Effective Tax Rate | 3.84% |
Stock Price Statistics
The stock price has increased by -14.55% in the
last 52 weeks. The beta is 0.95, so Lisata Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.95 |
| 52-Week Price Change | -14.55% |
| 50-Day Moving Average | 2.27 |
| 200-Day Moving Average | 2.78 |
| Relative Strength Index (RSI) | 49.26 |
| Average Volume (20 Days) | 13,500 |
Income Statement
In the last 12 months, Lisata Therapeutics had revenue of 1M
and earned -19.98M
in profits. Earnings per share was -2.4.
| Revenue | 1M |
| Gross Profit | 826K |
| Operating Income | -22.41M |
| Net Income | -19.98M |
| EBITDA | -20.61M |
| EBIT | -22.41M |
| Earnings Per Share (EPS) | -2.4 |
Full Income StatementBalance Sheet
The company has 16.21M in cash and 137K in
debt, giving a net cash position of 16.07M.
| Cash & Cash Equivalents | 16.21M |
| Total Debt | 137K |
| Net Cash | 16.07M |
| Retained Earnings | -548.07M |
| Total Assets | 35M |
| Working Capital | 28.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -19.36M
and capital expenditures 0, giving a free cash flow of -19.36M.
| Operating Cash Flow | -19.36M |
| Capital Expenditures | n/a |
| Free Cash Flow | -19.36M |
| FCF Per Share | -2.32 |
Full Cash Flow StatementMargins
Gross margin is 82.6%, with operating and profit margins of -2240.9% and -1998.5%.
| Gross Margin | 82.6% |
| Operating Margin | -2240.9% |
| Pretax Margin | -2078.3% |
| Profit Margin | -1998.5% |
| EBITDA Margin | -2060.9% |
| EBIT Margin | -2240.9% |
| FCF Margin | -1935.6% |
